Title: Apolipoproteins and Their Correlation with Some Early Markers of Vascular Disease in Subjects at Different Risk Categories
Authors: Muhammad Tawfik khattab, Ibrahim Naguib Al Ebrashy, Dawlat Ibrahim Salem*, Ahmad Amin Heikal & Mohamed Mohamed Ahmad Ibrahim
DOI: https://dx.doi.org/10.18535/jmscr/v4i12.69
Abstract
Objective: This study was conducted to study the correlation between plasma apolipoproteins (Apo A-1, ApoB & the ratio of ApoB to ApoA-1) and carotid intima-media thickness in subjects at different degrees of risk for cardiovascular disease.
Material & Methods: The study included 80 subjects selected from the employee of kasr Al aini Shool of medicine. All subjects were subjected to clinical assessment & laboratory investigations including lipid profile, apolipoproteins B & A1, CRP & microalbuminurea. Finally CIMT was performed to all our subjects.
Results: Our results showed statistically significant negative correlation between apo- A1 versus Framingham, SCORE system & Number of risks, and significant positive correlation with HDL. There was also statistically significant positive correlation between apo-B versus Framingham , SCORE system, Number of risks, cholesterol and LDL & statistically significant positive correlation between Apo-B / Apo A-1 versus Framingham , SCORE system, number of risks ,total cholesterol, LDL and negative correlation to HDL. Our subjects who were positive with metabolic syndrome had higher CIMT, higher apo B, higher apo-B/ apo A-1 ratio, lower apo-A compared to subjects without metabolic syndrome. There was also statistically significant positive correlation between carotid intima media thickness (cIMT) versus age, SBP, apo B, apo B/A-1, microalbuminuria and negatively correlated to apo A-1.
Conclusion: We conclude from the results in our study that the estimation of the apo B to apo A-1 ratio and the use of the number of risk factors as a score system for the estimation of cardiovascular risk show a strong association with CIMT which can be of significant importance in delineating vascular risk.
Key Words: apolipoprotein B, apolipoprotein A-1, atherosclerosis, CIMT, hsCRP.
References
1. 1. Jaspinder Kaur. A Comprehensive Review on Metabolic Syndrome. Cardiology Research and Practice Volume- 2014 (2014), Article ID 943162, 21 page.
2. 55% Gori T, Muxel S, Damaske A, Radmacher MC, Fasola F, 55%Schaefer S, 55%Schulz A, 55%Jabs A, 55%Parker JD, Münzel T. Endothelial function assessment: flow-mediated dilation and constriction provide different and complementary information on the presence of coronary artery disease. Eur Heart J. 2012 Feb;33(3):363-71. First published online: 14 September 2011
3. Mariarita Dessì, Annalisa Noce, -Pierfr-ancesco Bertucci, Simone Manca di Villahermosa, Rossella Zenobi, Veronica Castagnola, Eliana Addessi, and Nicola Di Daniele. Atherosclerosis, Dyslipidemia, and Inflammation: The Significant Role of Polyunsaturated Fatty Acids. Vol 2013 (2013), Article ID 191823, 13 pages.
4. Lokhande Suryabhan L, Iyer Chandrashekhar M, Shinde Ratnendra R, Nandedkar Prerna D, Kamble Mahendra T. Prognostic significance of Apolipoprotein B over traditional lipid parameters in atherosclerosis risk management in Type 2 diabetes mellitus. JPBMS, 2012, 21 (16)
5. Koren N, Goldbourt U, Graff E , et al. Apolipoproteins B and AI and the risk of ischemic cerebrovascular events in patients with pre-existing atherothrombotic disease, Journal of the Neurological Sciences 2008 ; 270 :82–87.
6. Cooney M T, Dudina A and D'Agostino R. Cardiovascular Risk-Estimation Systems in Primary Prevention : Do They Differ? Do They Make a Difference? Can We See the Future? Circulation. 2010;122:300-310.
7. Mookadam, F., Moustafa, S. E., Lester, S. J. and Warsame, T. (2010), Subclinical Atherosclerosis: Evolving Role of Carotid Intima-Media Thickness. Preventive Cardiology, 13: 186–197.
8. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS; American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008 Feb;21(2):93-111; quiz 189-90. doi: 10.1016/j.echo.2007.11.011.
9. Lundberg, C., Hansen, T., Ahlström, H., Lind, L., Wikström, J. and Johansson, L. (2014), The relationship between carotid intima–media thickness and global atherosclerosis. Clinical Physiology and Functional Imaging, 34: 457–462. doi: 10.1111/cpf.12116
10. Rodolfo Paoletti,Chiara Bolego, Andrea Poli, and Andrea Cignarella. Metabolic Syndrome, Inflammation and Atherosclerosis Vasc Health Risk Manag. Jun 2006; 2(2): 145–152.
11. Canadian Diabetes Association. clinical practice guidelines Expert committee. Dyslipidemia in adults with diabetes. Can J Diabetes. 2006; 20:230-40.
12. Geuroulakos GO, Gorman D, Nicolaides A, Sheridan D, Elkeler R and Shaper A: Carotid intima-media thickness, correlation with the British regional heart study risk score journal of Int. Med,1994; 235: 431-433.
13. Koracevic D and Koracevic G. J . Clin .Pathol, 2001; 54: 356 – 361.
14. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.
15. National Cholesterol Education Program (NCEP) .Third Report , Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143–3421.
16. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.
17. Hrira M, Kerkenic M, Hamdad BK, et al. Apolipoprotein A-I, apolipoprotein B, high-sensitivity C-reactive protein and severity of coronary artery disease in tunisian population , Cardiovascular Pathology 2012; 21: 455–460.
18. Suvorava T and Kojda G. Reactive oxygen species as cardiovascular mediators: Lessons from endothelial-specific protein overexpression mouse models. Biochim Biophys Acta.2009; 1787(7):802-10.
19. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43
20. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
21. Pavel Poredos. Markers of Preclinical Atherosclerosis and their Clinical Relevance.The Open Atherosclerosis & Thrombosis Journal, 2011, 4, 1-10
22. Rajaram V, Pandhya S, Patel S, et al. Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. Am J Cardiol. 2004; 93(11A): 32-48.
23. Smita IN and Nambi V. Current atheroscelerosis reports 2012; 14:115-123.
24. Leiter LA, Fitchett DH, Gilbert RE, et al. Cardiometabolic Risk Working Group: Executive Committee, Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can J Cardiol. 2011;27(2):124-31.
25. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008; 51:1512–1524.
26. Palaniappan L, Carnethon M and Fortmann SP.Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003; 16:952-8.
27. Belfki H, Ben Ali S, Bougatef S, et al. The Apolipoprotein B/Apolipoprotein A 1 ratio in relation to metabolic syndrome and its components in a sample of the Tunisian population. Exp Mol Pathol. 2011 Oct;91(2):622-5.
28. Hartley TA, Shankar A, Fekedulegn D, et al. Metabolic syndrome and carotid intima media thickness in urban police officers. J Occup Environ Med. 2011;53(5):553-61.
29. Rodondi N, Patrick Y, Anne G, et al. Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults Nephrol Dial Transplant 2007; 22: 1107–1114.
30. Shin D , Seung K, Seo S M, et al . clinical assessment of the association between microalbuminuria and predictors of atherosclerosis, JACC , 2012 volume 59, issue 13: 189-485.
31. Jadhav UM and Kadam NN. Apolipoproteins: Correlation with Carotid Intima-Media Thickness and Coronary Artery Disease Indian Heart J. 2004; 53:370-375.
32. Kampoli A, Tousoulis D, Antoniades C, et al. Biomarkers of premature atheroscle-rosis ,trends in molecular medicine 2009; Vol.15 No.7 ,223-232
33. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004; 364:937-52.
34. Benn M, Nordestgaard BG, Jensen GB, et al. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arteriosc-ler. Thromb. Vasc. Biol.2007; 27: 661–670.
35. Paul S. Jellinger; Donald A. Smith; Adi E. Mehta; Om Ganda; Yehuda Handelsma; Helena W. Rodbard; Mark D. Shepherd; John A. Seibel;the AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract.2012;18(suppl 1).
36. Takebayashi K, Suetsugu M, Matsutomo R, et al. Correlation of high-sensitivity C-reactive protein and plasma fibrinogen with individual complications in patients with type 2 diabetes. Southern Medical Journal 2006, 99(1):23-27.
37. Bo M, Corsinovi L, Brescianini A, et al. High-sensitivity C-reactive protein is not independently associated with peripheral subclinical atherosclerosis. Angiology 2009; 60: 12–20.
38. Lorenz MW, Markus HS, Bots ML, et al. High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the carotid atherosclerosis progression study. Stroke 2007; 38: 1774–1779.
39. Rifai N, Joubran R, Yu H, et al. Inflammatory markers in men with angiog-raphically documented coronary heart disease. Clin Chem 1999; 45:1967–73.
40. Azar RR, Aoun G, Fram DB, et al. Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. Am J Cardiol 2000; 86:205–8.
41. Haverkate F, Thompson SG, Pyke SD, et al. for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coro-nary events in stable and unstable angina. Lancet 1997; 349:462–6.
42. Zebrack JS, Muhlestein JB, Horne BD, et al. Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in sub-jects with angina. J Am Coll Cardiol 2002; 39: 632–7.
43. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammati-on/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc 2001;286: 64-70.
44. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; Vol.103: 342–348.
45. Musial J, Undas A, Gajewski P, et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001; Vol.77, pp.247-53.